ChargePoint Technology expands smart monitoring technology into North America
Company's VERIFI smart monitoring hub allows production teams to manage and maintain their containment solution which, in turn, helps assure operator safety and sterility assurance related performance during pharmaceutical manufacturing processes.
Powder containment and sterile transfer solutions provider, ChargePoint Technology has achieved HazLoc (Hazardous Area) certification for VERIFI to further support customers in North America.
The HazLoc certification has been granted by the Canadian Standards Association (CSA) and will enable ChargePoint to expand its VERIFI smart monitoring hub into the North American market.
The VERIFI smart monitoring hub is a first-of-its-kind technology which monitors usage of ChargePoint’s split butterfly valve (SBV), used to provide containment during pharmaceutical manufacturing.
VERIFI continuously records valve-use providing data that allows production teams to manage and maintain their containment solution in a proactive and efficient manner. In turn, this helps assure operator safety and sterility assurance related performance during pharmaceutical manufacturing processes.
Chris Rombach, president at ChargePoint Technology commented: “Having seen the positive impact and excellent response to VERIFI in European markets, we are proud to bring VERIFI to North America. We can now give our customers more autonomy to improve operational performance and productivity, as well as helping them manage risk in their manufacturing processes.”
ChargePoint Technology has worked closely with CSA over the last two years to achieve the certification for Class 1 Zone 0 and Class II/III Zone 21, which was granted after an inspection of the company’s Liverpool, UK manufacturing headquarters in late 2018.
The company already holds Atmosphere Explosive (ATEX) and International Electro Commission (IEC) Explosive (Ex) certifications, allowing the use of VERIFI in hazardous environments in Europe.
Adam Bunyard, director of innovation and technology at ChargePoint Technology said: “Our customer base in the North American market is rapidly growing and we are excited to now be able to support existing and future customers with our unique smart monitoring technology.
“As the industry moves towards Industry 4.0, ChargePoint will remain at the forefront of contained transfer innovation, responding to the challenges of today and tomorrow.”
ChargePoint Technology’s solutions also include its AseptiSafe range of SBVs, designed to increase sterility assurance for ingredient and small component transfers in aseptic processing.
All of ChargePoint Technology’s transfer solutions are independently performance tested to the ISPE SMEPAC guidelines. The company works with select material handling solution partners globally to ensure an integrated high containment handling process is successfully achieved.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.